Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry

Cell Reports

Volumn 22, Issue 7, 2018, Pages 1875-1888

  Gonzalez, Veronica D ^a   Samusik, Nikolay ^a   Chen, Tiffany J ^a,h   Savig, Erica S ^a,i   Aghaeepour, Nima ^a   Quigley, David A ^b,c   Huang, Ying Wen ^a   Giangarrà, Valeria ^a   Borowsky, Alexander D ^d,e   Hubbard, Neil E ^d,e   Chen, Shih Yu ^a   Han, Guojun ^a   Ashworth, Alan ^b,c   Kipps, Thomas J ^f   Berek, Jonathan S ^g   Nolan, Garry P ^a   Fantl, Wendy J ^g  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g STANFORD CANCER INSTITUTE   (United States)

^h ILLUMINA INC   (United States)

ⁱ weLeap labs LLC   (United States)

Author keywords

cMyc; CyTOF; HE4; heterogeneity; hierarchical clustering; high grade serious ovarian cancer; mass cytometry; phenotypic characterization; relapse; single cell

Indexed keywords

CARBOPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UVOMORULIN; VIMENTIN; CANCER ANTIBODY; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE; CELL POPULATION; CELLULAR DISTRIBUTION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MASS CYTOMETRY; METASTASIS; MULTIPARAMETRIC MASS CYTOMETRY; OVARY TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; AGED; CLUSTER ANALYSIS; CYSTADENOCARCINOMA; DRUG EFFECT; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; TUMOR CELL LINE; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; CARBOPLATIN; CELL LINE, TUMOR; CLUSTER ANALYSIS; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PHENOTYPE; PROGNOSIS;

EID: 85042014630     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.01.053     Document Type: Article

References (69)

1. Ahmed, A.A., Etemadmoghadam, D., Temple, J., Lynch, A.G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., Defazio, A., et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221 (2010), 49–56.
2. Anchang, B., Hart, T.D., Bendall, S.C., Qiu, P., Bjornson, Z., Linderman, M., Nolan, G.P., Plevritis, S.K., Visualization and cellular hierarchy inference of single-cell data using SPADE. Nat. Protoc. 11 (2016), 1264–1279.
3. Arakawa, A., Nishikawa, H., Suzumori, K., Kato, N., Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer. Int. J. Clin. Oncol. 6 (2001), 248–252.
4. Au-Yeung, G., Lang, F., Azar, W.J., Mitchell, C., Jarman, K.E., Lackovic, K., Aziz, D., Cullinane, C., Pearson, R.B., Mileshkin, L., et al. Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin. Cancer Res. 23 (2017), 1862–1874.
5. Baldwin, L.A., Hoff, J.T., Lefringhouse, J., Zhang, M., Jia, C., Liu, Z., Erfani, S., Jin, H., Xu, M., She, Q.B., et al. CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget 5 (2014), 12203–12217.
6. Behbehani, G.K., Thom, C., Zunder, E.R., Finck, R., Gaudilliere, B., Fragiadakis, G.K., Fantl, W.J., Nolan, G.P., Transient partial permeabilization with saponin enables cellular barcoding prior to surface marker staining. Cytometry A 85 (2014), 1011–1019.
7. Bendall, S.C., Simonds, E.F., Qiu, P., Amir, E.-A.D., Krutzik, P.O., Finck, R., Bruggner, R.V., Melamed, R., Trejo, A., Ornatsky, O.I., et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332 (2011), 687–696.
8. Bjornson, Z.B., Nolan, G.P., Fantl, W.J., Single-cell mass cytometry for analysis of immune system functional states. Curr. Opin. Immunol. 25 (2013), 484–494.
9. Borley, J., Wilhelm-Benartzi, C., Brown, R., Ghaem-Maghami, S., Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br. J. Cancer 107 (2012), 1069–1074.
10. Bowtell, D.D., Böhm, S., Ahmed, A.A., Aspuria, P.J., Bast, R.C. Jr., Beral, V., Berek, J.S., Birrer, M.J., Blagden, S., Bookman, M.A., et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15 (2015), 668–679.
11. Brumer, Y., Michor, F., Shakhnovich, E.I., Genetic instability and the quasispecies model. J. Theor. Biol. 241 (2006), 216–222.
12. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
13. Chen, G.M., Kannan, L., Geistlinger, L., Kofia, V., Safikhani, Z., Gendoo, D.M.A., Parmigiani, G., Birrer, M., Haibe-Kains, B., and Waldron, L. (2017). Consensus on molecular subtypes of ovarian cancer. Published online July 12, 2017. 10.1101/162685.
14. Cingolani, P., Platts, A., Wang, L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, X., Ruden, D.M., A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6 (2012), 80–92.
15. Ciriello, G., Miller, M.L., Aksoy, B.A., Senbabaoglu, Y., Schultz, N., Sander, C., Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45 (2013), 1127–1133.
16. Coscia, F., Watters, K.M., Curtis, M., Eckert, M.A., Chiang, C.Y., Tyanova, S., Montag, A., Lastra, R.R., Lengyel, E., Mann, M., Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat. Commun., 7, 2016, 12645.
17. Davidson, B., CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. Hum. Pathol. 58 (2016), 123–127.
18. Davidson, B., Tropé, C.G., Reich, R., Epithelial-mesenchymal transition in ovarian carcinoma. Front. Oncol., 2, 2012, 33.
19. Etemadmoghadam, D., George, J., Cowin, P.A., Cullinane, C., Kansara, M., Gorringe, K.L., Smyth, G.K., Bowtell, D.D., Australian Ovarian Cancer Study Group. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS ONE, 5, 2010, e15498.
20. Fienberg, H.G., Simonds, E.F., Fantl, W.J., Nolan, G.P., Bodenmiller, B., A platinum-based covalent viability reagent for single-cell mass cytometry. Cytometry A 81 (2012), 467–475.
21. Filippakopoulos, P., Knapp, S., Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13 (2014), 337–356.
22. Finck, R., Simonds, E.F., Jager, A., Krishnaswamy, S., Sachs, K., Fantl, W., Pe'er, D., Nolan, G.P., Bendall, S.C., Normalization of mass cytometry data with bead standards. Cytometry A 83 (2013), 483–494.
23. Ganesan, S., MYC, PARP1, and chemoresistance: BIN there, done that?. Sci. Signal., 4, 2011, pe15.
24. Gaudillière, B., Fragiadakis, G.K., Bruggner, R.V., Nicolau, M., Finck, R., Tingle, M., Silva, J., Ganio, E.A., Yeh, C.G., Maloney, W.J., et al. Clinical recovery from surgery correlates with single-cell immune signatures. Sci. Transl. Med., 6, 2014, 255ra131.
25. Greaves, M., Evolutionary determinants of cancer. Cancer Discov. 5 (2015), 806–820.
26. Han, G., Chen, S.Y., Gonzalez, V.D., Zunder, E.R., Fantl, W.J., Nolan, G.P., Atomic mass tag of bismuth-209 for increasing the immunoassay multiplexing capacity of mass cytometry. Cytometry A. 91 (2017), 1150–1163.
27. Hemler, M.E., Tetraspanin proteins promote multiple cancer stages. Nat. Rev. Cancer 14 (2014), 49–60.
28. Horowitz, A., Strauss-Albee, D.M., Leipold, M., Kubo, J., Nemat-Gorgani, N., Dogan, O.C., Dekker, C.L., Mackey, S., Maecker, H., Swan, G.E., et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci. Transl. Med., 5, 2013, 208ra145.
29. Hotson, A.N., Gopinath, S., Nicolau, M., Khasanova, A., Finck, R., Monack, D., Nolan, G.P., Coordinate actions of innate immune responses oppose those of the adaptive immune system during Salmonella infection of mice. Sci. Signal., 9, 2016, ra4.
30. Huang, R.Y., Wong, M.K., Tan, T.Z., Kuay, K.T., Ng, A.H., Chung, V.Y., Chu, Y.S., Matsumura, N., Lai, H.C., Lee, Y.F., et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis., 4, 2013, e915.
31. Ideker, T., Krogan, N.J., Differential network biology. Mol. Syst. Biol., 8, 2012, 565.
32. Jiang, S.W., Chen, H., Dowdy, S., Fu, A., Attewell, J., Kalogera, E., Drapkin, R., Podratz, K., Broaddus, R., Li, J., HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int. J. Mol. Sci. 14 (2013), 22655–22677.
33. Jolly, M.K., Boareto, M., Huang, B., Jia, D., Lu, M., Ben-Jacob, E., Onuchic, J.N., Levine, H., Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front. Oncol., 5, 2015, 155.
34. Jolly, M.K., Ward, C., Eapen, M.S., Myers, S., Hallgren, O., Levine, H., Sohal, S.S., Epithelial-mesenchymal transition, a spectrum of states: role in lung development, homeostasis, and disease. Dev. Dyn., 2017 Published online July 21, 2017. 10.1002/dvdy.24541.
35. Köbel, M., Piskorz, A.M., Lee, S., Lui, S., LePage, C., Marass, F., Rosenfeld, N., Mes Masson, A.M., Brenton, J.D., Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J. Pathol. Clin. Res. 2 (2016), 247–258.
36. Konecny, G.E., Wang, C., Hamidi, H., Winterhoff, B., Kalli, K.R., Dering, J., Ginther, C., Chen, H.W., Dowdy, S., Cliby, W., et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl. Cancer Inst., 106, 2014, dju249.
37. Kotecha, N., Krutzik, P.O., Irish, J.M., Web-based analysis and publication of flow cytometry experiments. Curr. Protoc. Cytom. 53 (2010), 10.17.1–10.17.24.
38. Krogan, N.J., Lippman, S., Agard, D.A., Ashworth, A., Ideker, T., The cancer cell map initiative: defining the hallmark networks of cancer. Mol. Cell 58 (2015), 690–698.
39. Kruskal, J.B., On the shortest spanning subtree of a graph and the traveling salesman problem. Proc. Am. Math. Soc. 7 (1956), 48–50.
40. Krzystyniak, J., Ceppi, L., Dizon, D.S., Birrer, M.J., Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer. Ann. Oncol. 27:Suppl 1 (2016), i4–i10.
41. Levine, J.H., Simonds, E.F., Bendall, S.C., Davis, K.L., Amir, A.D., Tadmor, M.D., Litvin, O., Fienberg, H.G., Jager, A., Zunder, E.R., et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162 (2015), 184–197.
42. Li, H., Durbin, R., Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25 (2009), 1754–1760.
43. Li, J., Chen, H., Mariani, A., Chen, D., Klatt, E., Podratz, K., Drapkin, R., Broaddus, R., Dowdy, S., Jiang, S.W., HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines. Int. J. Mol. Sci. 14 (2013), 6026–6043.
44. Li, J., Chen, H., Curcuru, J.R., Patel, S., Johns, T.O., Patel, D., Qian, H., Jiang, S.W., Serum HE4 level as a biomarker to predict the recurrence of gynecologic cancers. Curr. Drug Targets 18 (2017), 1158–1164.
45. Lu, R., Sun, X., Xiao, R., Zhou, L., Gao, X., Guo, L., Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem. Biophys. Res. Commun. 419 (2012), 274–280.
46. Marusyk, A., Almendro, V., Polyak, K., Intra-tumour heterogeneity: a looking glass for cancer?. Nat. Rev. Cancer 12 (2012), 323–334.
47. Matulonis, U.A., Sood, A.K., Fallowfield, L., Howitt, B.E., Sehouli, J., Karlan, B.Y., Ovarian cancer. Nat. Rev. Dis. Primers, 2, 2016, 16061.
48. McAllister, S.S., Weinberg, R.A., The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat. Cell Biol. 16 (2014), 717–727.
49. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., DePristo, M.A., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20 (2010), 1297–1303.
50. Medrano, M., Communal, L., Brown, K.R., Iwanicki, M., Normand, J., Paterson, J., Sircoulomb, F., Krzyzanowski, P., Novak, M., Doodnauth, S.A., et al. Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer. Cell Rep. 18 (2017), 2343–2358.
51. Moore, R.G., Hill, E.K., Horan, T., Yano, N., Kim, K., MacLaughlan, S., Lambert-Messerlian, G., Tseng, Y.D., Padbury, J.F., Miller, M.C., et al. HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci. Rep., 4, 2014, 3574.
52. O'Gorman, W.E., Hsieh, E.W., Savig, E.S., Gherardini, P.F., Hernandez, J.D., Hansmann, L., Balboni, I.M., Utz, P.J., Bendall, S.C., Fantl, W.J., et al. Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus. J. Allergy Clin. Immunol. 136 (2015), 1326–1336.
53. Riester, M., Wei, W., Waldron, L., Culhane, A.C., Trippa, L., Oliva, E., Kim, S.H., Michor, F., Huttenhower, C., Parmigiani, G., Birrer, M.J., Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J. Natl. Cancer Inst., 106, 2014, dju048.
54. Samusik, N., Good, Z., Spitzer, M.H., Davis, K.L., Nolan, G.P., Automated mapping of phenotype space with single-cell data. Nat. Methods 13 (2016), 493–496.
55. Schwarz, R.F., Ng, C.K., Cooke, S.L., Newman, S., Temple, J., Piskorz, A.M., Gale, D., Sayal, K., Murtaza, M., Baldwin, P.J., et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med., 12, 2015, e1001789.
56. Shibue, T., Weinberg, R.A., EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14 (2017), 611–629.
57. Spitzer, M.H., Nolan, G.P., Mass cytometry: single cells, many features. Cell 165 (2016), 780–791.
58. Spitzer, M.H., Carmi, Y., Reticker-Flynn, N.E., Kwek, S.S., Madhireddy, D., Martins, M.M., Gherardini, P.F., Prestwood, T.R., Chabon, J., Bendall, S.C., et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168 (2017), 487–502.e15.
59. Stewart, J.M., Shaw, P.A., Gedye, C., Bernardini, M.Q., Neel, B.G., Ailles, L.E., Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc. Natl. Acad. Sci. USA 108 (2011), 6468–6473.
60. Tabassum, D.P., Polyak, K., Tumorigenesis: it takes a village. Nat. Rev. Cancer 15 (2015), 473–483.
61. Tothill, R.W., Tinker, A.V., George, J., Brown, R., Fox, S.B., Lade, S., Johnson, D.S., Trivett, M.K., Etemadmoghadam, D., Locandro, B., et al., Australian Ovarian Cancer Study Group. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14 (2008), 5198–5208.
62. Unger, F., Bentz, S., Kruger, J., Rosenbrock, C., Schaller, J., Pursche, K., Sprussel, A., Juhl, H., David, K., Precision cut cancer tissue slices in anti-cancer drug testing. J. Mol. Pathophysiol., 4, 2015, 108.
63. Unger, F.T., Krüger, J., Juhl, H., David, K.A., Drug profiling in precision cut cancer tumor slices: analysis of therapeutic antibodies in colorectal cancer. Int. J. Cancer Immunol. Immun. 1 (2015), 1–8.
64. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
65. Wang, Z.C., Birkbak, N.J., Culhane, A.C., Drapkin, R., Fatima, A., Tian, R., Schwede, M., Alsop, K., Daniels, K.E., Piao, H., et al., Australian Ovarian Cancer Study Group. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin. Cancer Res. 18 (2012), 5806–5815.
66. Ye, X., Weinberg, R.A., Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 25 (2015), 675–686.
67. Zhang, S., Cui, B., Lai, H., Liu, G., Ghia, E.M., Widhopf, G.F. 2nd, Zhang, Z., Wu, C.C., Chen, L., Wu, R., et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc. Natl. Acad. Sci. USA 111 (2014), 17266–17271.
68. Zhang, H., Liu, T., Zhang, Z., Payne, S.H., Zhang, B., McDermott, J.E., Zhou, J.Y., Petyuk, V.A., Chen, L., Ray, D., et al., CPTAC Investigators. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166 (2016), 755–765.
69. Zunder, E.R., Finck, R., Behbehani, G.K., Amir, E.-A.D., Krishnaswamy, S., Gonzalez, V.D., Lorang, C.G., Bjornson, Z., Spitzer, M.H., Bodenmiller, B., et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat. Protoc. 10 (2015), 316–333.